BioMarin Pharmaceutical stock holds near a $12.38 billion value

Published on 09/20/2026 at 21:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin Pharmaceutical stock closed at USD 63.94 on September 18, 2026. MarketBeat puts the market value at USD 12.38 billion and the consensus target at USD 89.17.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin Pharmaceutical Inc. (US09061G1013) stock closed at USD 63.94 on September 18, 2026, down USD 1.14 or 1.75 percent, with a market value of USD 12.38 billion. MarketBeat also shows a 52-week range of USD 49.26 to USD 70.98 and volume of 4.46 million shares.

Latest report still matters

According to MarketBeat on September 20, 2026, BioMarin carries a consensus rating of Moderate Buy and a consensus price target of USD 89.17, about 39.5 percent above the last close. The same page lists 23 analysts, 1 strong buy, 15 buy, 6 hold and 1 sell rating.

MarketBeat says trailing-twelve-month EPS was USD 0.37, while the stock traded at a P/E ratio of 172.81 on September 18, 2026. For investors, that gap between earnings and valuation remains the key tension.

Price and valuation

The shares are sitting 9.9 percent below the 52-week high of USD 70.98 and 29.1 percent above the 52-week low of USD 49.26, both on MarketBeat's September 20, 2026 snapshot. The close of USD 63.94 is the reference point for the current setup.

According to MarketBeat on September 20, 2026, the stock's market capitalization stood at USD 12.38 billion and average volume at 1.69 million shares. That places BioMarin in a valuation band where earnings delivery matters more than momentum.

Trading around support

BioMarin Pharmaceutical stock is trading below its 52-week high but above its yearly low, with the latest close at USD 63.94 on September 18, 2026. The next visible reference on the tape is the USD 89.17 consensus target from MarketBeat.